Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (10584)	6/29/1999 8:38:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I think there is a lot to be said for T.A. Would have avoided buying so early if I had paid more attention. BTW am on my second reading of the annual meeting presentation on the XOMA web site. Just a great presentation. However if you get into an automobile accident it apparently makes you sstutter if it is ssever enough. Short example of one of the many things I found of interest. <<<<< Our LBP assay has three licensees: Biosite Diagnostics is in the clinic, DPC is expected to enter the European market by the end of this year, and SRL is in preclinical studies in Japan.>>>>>>> <<<<<<<< DPC is expected to enter the European market by the end of this year, >>>>>>> We might have both news and royalties as a result of the DPC product this year. IMO. BTW all the Castello/XOMA remarks come with a standard non K but rather a S.E.C. approved disclaimer. So best visit the site to read it there. Am surprised there have been no comments yet.

To: Arthur Radley who wrote (10584)	6/29/1999 11:14:00 PM
From: Edscharp	Read Replies (1) \| Respond to of 17367

TexasDude, I'm sure your aware of this, but I'll say it anyway. Technical Analysis (TA) can occasionally be very useful, but in this context I think it is near useless. If Neuprex fails to perform the stock will drop like a rock. The false assumption is that TA can somehow predict this. The technical chart looks good because of investor expectations that Neuprex will succeed. If it doesn't succeed TA will quickly reflect the new reality. TA is great if it can predict a stock's movement the day before, not the day after. TA works a hell of a lot better when a company has earnings.